Gold prices remain near record highs; Fed cut bets prompt weekly gains
On Friday, Needham reaffirmed its Hold rating on Cooper Companies (NASDAQ:COO), a $18.16 billion medical device company trading near its 52-week low, after the company reported its first quarter of fiscal year 2025 results. According to InvestingPro data, the stock has shown historically low price volatility, making this current price level particularly noteworthy for investors. The firm highlighted that Cooper Companies’ revenue for the quarter fell short of market expectations due to weaker sales in its Sphere & Other segment within Cooper Vision (CVI) and its Fertility segment in Cooper Surgical (CSI). The revenue miss was attributed to a 4% shortfall in CVI and a 7% miss in CSI, with specific challenges noted in China and a sluggish beginning to the quarter in the United States for CVI, and difficult year-over-year and quarter-over-quarter comparisons for CSI.
Despite the revenue miss, Cooper Companies managed to surpass earnings per share (EPS) estimates by a slight margin, beating consensus by one cent. The analyst from Needham pointed out that the company’s performance suggests that the strength in Cooper Vision is expected to be more pronounced in the second half of fiscal year 2025. This outlook is based on the commentary provided by the company, indicating a potential rebound in the later quarters.
Furthermore, the guidance provided by Cooper Companies does not currently account for the impact of foreign exchange rates. The Needham analyst noted that if the current foreign exchange rates persist, they could potentially aid the company in achieving or even surpassing the higher end of its guidance range. Despite these factors, Needham has decided to maintain its Hold rating on the stock.
Investors and stakeholders are keeping a close watch on Cooper Companies as the firm navigates through its fiscal year, with particular attention being paid to the anticipated stronger performance in the latter half and the possible benefits from foreign exchange rates that have yet to be factored into the company’s financial guidance. The company’s next earnings report is scheduled for May 29, 2025. InvestingPro subscribers can access additional insights through the comprehensive Pro Research Report, which includes detailed analysis of Cooper Companies’ valuation metrics, growth prospects, and financial health indicators.
In other recent news, Cooper Companies reported its first-quarter earnings for 2025, revealing a non-GAAP earnings per share (EPS) of $0.92, which met analysts’ expectations. The company achieved consolidated revenues of $965 million, slightly below the forecast of $979.7 million, marking a 4% year-over-year increase. Despite the revenue miss, Cooper Companies reaffirmed most of its guidance, attributing this decision to improving supply dynamics in the contact lens market and the continued strength of the Fertility market. Jefferies analyst Young Li adjusted the price target for Cooper Companies shares to $110 from $115, while maintaining a "Buy" rating, reflecting recent quarterly performance and market conditions.
Meanwhile, KeyBanc analyst Brett Fishbin maintained a Sector Weight rating on Cooper Companies stock, noting that despite first-quarter challenges, the company kept its organic growth guidance steady. Cooper Companies plans to focus on reducing its debt and investing in capacity for its CooperVision segment, which could shape its financial strategy in the near term. The company’s Sphere segment experienced a 3% growth, with stronger performances in the Toric and Multifocal segments, both seeing a 10% growth. The Fertility segment faced a challenging quarter-over-quarter comparison due to robust fourth-quarter capital sales. These developments highlight Cooper Companies’ ongoing efforts to navigate market dynamics and sustain growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.